Myeloperoxidase Marker of Inflammation in Obese Children
Marker associated with higher risk of CVD in obese prepubertal children
MONDAY, Aug. 27 (HealthDay News) -- In obese prepubertal children, myeloperoxidase (MPO) is an early biomarker of inflammation and cardiovascular disease risk, according to a study published online Aug. 21 in Diabetes Care.
Josune Olza, Ph.D., from the University of Granada in Spain, and colleagues conducted a prospective multicenter case-control study, in which 446 Caucasian prepubertal children (aged 6 to 12 years; 223 normal-weight and 223 obese) were matched by age and sex. Serum biomarkers of inflammation and cardiovascular disease, including MPO, glucose, insulin, metabolic lipid parameters, oxidized low-density lipoproteins, adiponectin, leptin, resistin, C-reactive protein (CRP), interleukin 6, tumor necrosis factor α, matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor 1, were assessed.
The researchers found that MPO was elevated in prepubertal obese children. MPO was associated with proinflammatory and cardiovascular risk biomarkers, including CRP, MMP-9, and resistin. The best predictor of MPO was insulin resistance, calculated by the homeostatic assessment model.
"The main findings of this study were that plasma MPO was elevated in prepubertal obese children and that this enzyme was associated with proinflammatory and cardiovascular risk factors," the authors write.